As part of the UK Government’s announcement of a new five pillar plan to boost testing for COVID-19, AstraZeneca, GSK and the University of Cambridge have formed a joint collaboration to take action to support this national effort.
Cambridge researchers have found the strongest evidence to date that human pluripotent stem cells – cells that can give rise to all tissues of the body – will develop normally once transplanted into an embryo. The findings, published today in the journal Cell Stem Cell, could have important implications for regenerative medicine.
Scientists at the University of Cambridge have successfully created ‘mini-lungs’ using stem cells derived from skin cells of patients with cystic fibrosis, and have shown that these can be used to test potential new drugs for this debilitating lung disease.
DefiniGEN is one of the first commercial opportunities to arise from Cambridge’s expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic cells for drug screening.
Cambridge team which developed method to generate liver cells from skin cells has formed a new company to supply stem cell products to the drug discovery and regenerative medicine sectors.
Much hyped by the media, stem cells have tremendous power to improve human health. As part of the Cambridge Stem Cell Initiative, Dr Ludovic Vallier’s research in the Anne McLaren Laboratory for Regenerative Medicine shows how stem cells can further our understanding of disease and help deliver much-needed new treatments.
© 2024 University of Cambridge